Related Experiment Video
Updated: May 26, 2025

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
Published on: September 20, 2018
Are Causal Statements Reported in Pharmacovigilance Disproportionality Analyses Using Individual Case Safety Reports
Claire Bernardeau1, Bruno Revol1,2, Francesco Salvo3,4
1Pharmacovigilance Unit, Grenoble Alpes University Hospital, University Grenoble Alpes, 38000, Grenoble, France.
Background:
Previous meta-epidemiological surveys have found considerable misinterpretation of results of disproportionality analyses. We aim to explore the relationship between the strength of causal statements used in title and abstract conclusions of pharmacovigilance disproportionality analyses and the strength of causal language used in citing studies.
Methods:
On March 30, 2022, we selected the 30 disproportionality studies with the highest Altmetric Attention Scores. For each article, we extracted all citing studies using the Dimension database (n = 1434). In parallel, two authors assessed the strength of causal statements in the title and abstract conclusions of source articles and in the paragraph of citing studies. Based on previous studies, the strength of causal language was quantified based on a four-level scale (1-appropriate interpretation; 2-ambiguous interpretation; 3-conditionally causal; 4-unconditionally causal). Discrepancies were solved by discussion until consensus among the team. We assessed the association between the strength of causal statements in source articles and citing studies, separately for the title and abstract conclusions, through multinomial regression models.
Results:
Overall, 27% (n = 8) of source studies used unconditionally causal statements in their title, 30% (n = 9) in their abstract conclusion, and 17% (n = 5) in both. Only 20% (n = 6) used appropriate statements in their title and in their abstract's conclusions. Among the 622 citing studies analyzed, 285 (45.8%) used unconditionally causal statements when referring to the findings from disproportionality analysis, and only 164 (26.4%) used appropriate language. Multinomial models found that the strength of causal statements in citing studies was positively associated with the strength of causal language used in abstract conclusions of source articles (Likelihood Ratio Test (LogLRT) p < 0.00001) but not in the titles. In particular, among studies citing source articles with appropriate interpretation, 30.2% (95% confidence interval [CI] 22.8-37.6) contained unconditionally causal statements in their abstract conclusions, versus 56.4% (95% CI 48.7-64.2) for studies citing source articles with unconditionally causal statements.
Conclusions:
Nearly half of the studies citing pharmacovigilance disproportionality analyses results used causal claims, particularly when the causal language used in the source article was stronger. There is a need for higher caution when writing, interpreting, and citing disproportionality studies.
More Related Videos
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
05:53Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
Related Concept Videos
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Hazard Ratio
For example, in a clinical trial...
Analysis of Population Pharmacokinetic Data
Criteria for Causality: Bradford Hill Criteria - II
Relative Risk